<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762463</url>
  </required_header>
  <id_info>
    <org_study_id>A3191348</org_study_id>
    <nct_id>NCT00762463</nct_id>
  </id_info>
  <brief_title>Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis</brief_title>
  <official_title>A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a local, multicenter, randomized, active comparator, double-blind, parallel group
      study with extension will be conducted to evaluate the efficacy and safety of celecoxib
      versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of less than (&lt;) 0 indicated improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant's Assessment of Global Pain Intensity at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4</measure>
    <time_frame>Baseline, Weeks 2, 4</time_frame>
    <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BASFI at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BASDAI at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20</measure>
    <time_frame>Weeks 2, 4, 6, 12</time_frame>
    <description>Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Pain at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fingertips to Floor Distance at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline &lt;0 represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chest Expansion at Weeks 2, 4, and 6</measure>
    <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
    <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (&gt;) 0 represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chest Expansion at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (&gt;) 0 represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP) at Week 6</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CRP was a marker of inflammation. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Concomitant Use of Paracetamol</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Concomitant Administration of Paracetamol</measure>
    <time_frame>Week 6</time_frame>
    <description>Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol Tablets Taken Per Day by Participant</measure>
    <time_frame>Week 6</time_frame>
    <description>Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Celecoxib 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac SR 75 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>capsule, 200 mg QD, 6-12 weeks</description>
    <arm_group_label>Celecoxib 200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac SR</intervention_name>
    <description>tablet, 75 mg QD,6-12 weeks</description>
    <arm_group_label>Diclofenac SR 75 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the 1984 Modified New York Criteria for Classification of Ankylosing Spondylitis

          -  With axial involvement

          -  Without peripheral joint involvement (synovitis) at the time of study entry,
             (excluding involvement of the hips, knees and shoulders)

          -  Need for daily treatment with NSAIDs during the previous 30 days before study entry

        Exclusion Criteria:

          -  Known inflammatory enteropathy (eg, ulcerative colitis, Crohn's disease, etc)

          -  Presence of extra-articular manifestations (eg, uveitis, endocarditis, etc.)

          -  Known vertebral compression

          -  Need for a corset during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191348&amp;StudyName=Study%20Of%20Celecoxib%20Or%20Diclofenac%20For%20Efficacy%20and%20Safety%20In%20Chinese%20Patients%20With%20Ankylosing%20Spondylitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>June 17, 2011</results_first_submitted>
  <results_first_submitted_qc>July 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2011</results_first_posted>
  <last_update_submitted>July 26, 2011</last_update_submitted>
  <last_update_submitted_qc>July 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Celecoxib 200 mg</title>
          <description>Celecoxib 200 milligram (mg) capsule once daily</description>
        </group>
        <group group_id="P2">
          <title>Diclofenac SR 75 mg</title>
          <description>Diclofenac sustained release (SR) 75 mg tablet once daily</description>
        </group>
        <group group_id="P3">
          <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
          <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
        </group>
        <group group_id="P4">
          <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
          <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase (Baseline to Week 6)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Enrollment in Extension Phase (Week 6)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not sign 2nd informed consent form</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase (Week 6 to Week 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib 200 mg</title>
          <description>Celecoxib 200 mg capsule once daily</description>
        </group>
        <group group_id="B2">
          <title>Diclofenac SR 75 mg</title>
          <description>Diclofenac SR 75 mg tablet once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6</title>
        <description>100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of less than (&lt;) 0 indicated improvement.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Per-Protocol (PP): All randomized participants who received at least one dose of study medication, and had global pain intensity assessment at Week 6 and no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6</title>
          <description>100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of less than (&lt;) 0 indicated improvement.</description>
          <population>Per-Protocol (PP): All randomized participants who received at least one dose of study medication, and had global pain intensity assessment at Week 6 and no major protocol deviations.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" spread="1.98"/>
                    <measurement group_id="O2" value="-27.1" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Least Squares (LS) mean difference between Celecoxib 200 mg once daily versus Diclofenac SR 75 mg once daily on change in Global Pain Intensity from baseline to Week 6 was at least 10 mm. Corresponding alternative hypothesis: This difference was &lt;10 mm.
For the non-inferiority test, power was 80% and significance level was 0.025 (1-sided).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>LS mean difference calculated as LS mean change for Celecoxib 200 mg once daily minus LS mean change for Diclofenac SR 75 mg once daily. Non-inferiority was declared if the upper bound of the 95% confidence interval was &lt;10 mm.</non_inferiority_desc>
            <p_value>0.0085</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA); factors: treatment group and study center; covariate: baseline Patient’s Assessment of Global Pain Intensity score.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant's Assessment of Global Pain Intensity at Baseline</title>
        <description>100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain.</description>
        <time_frame>Baseline</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Assessment of Global Pain Intensity at Baseline</title>
          <description>100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain.</description>
          <population>PP</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="12.68"/>
                    <measurement group_id="O2" value="63.6" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4</title>
        <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4</time_frame>
        <population>Full Analysis Set (FAS). Number of participants analyzed (N) = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4</title>
          <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Change from baseline of &lt;0 indicated improvement.</description>
          <population>Full Analysis Set (FAS). Number of participants analyzed (N) = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" spread="1.78"/>
                    <measurement group_id="O2" value="-17.9" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="1.86"/>
                    <measurement group_id="O2" value="-23.3" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7849</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3223</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12</title>
        <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12</title>
          <description>100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question &quot;What has been your global pain intensity in the last 48 hours?&quot; 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="13.58"/>
                    <measurement group_id="O2" value="61.1" spread="13.08"/>
                    <measurement group_id="O3" value="63.4" spread="12.05"/>
                    <measurement group_id="O4" value="65.6" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="21.39"/>
                    <measurement group_id="O2" value="-30.9" spread="24.24"/>
                    <measurement group_id="O3" value="-20.8" spread="21.86"/>
                    <measurement group_id="O4" value="-28.1" spread="25.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6</title>
        <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6</title>
          <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.06"/>
                    <measurement group_id="O2" value="-0.4" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.06"/>
                    <measurement group_id="O2" value="-0.4" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.06"/>
                    <measurement group_id="O2" value="-0.4" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8938</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0426</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1502</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12</title>
        <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12</title>
          <description>5-point Likert scale scores specified participant's current situation in response to the following question &quot;Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?&quot; 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.83"/>
                    <measurement group_id="O2" value="3.0" spread="0.64"/>
                    <measurement group_id="O3" value="3.2" spread="0.66"/>
                    <measurement group_id="O4" value="3.2" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.99"/>
                    <measurement group_id="O2" value="-0.6" spread="0.78"/>
                    <measurement group_id="O3" value="-0.4" spread="0.71"/>
                    <measurement group_id="O4" value="-0.6" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6</title>
        <description>5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6</title>
          <description>5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.05"/>
                    <measurement group_id="O2" value="-0.4" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.05"/>
                    <measurement group_id="O2" value="-0.5" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.06"/>
                    <measurement group_id="O2" value="-0.5" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5945</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3427</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6522</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</title>
        <description>5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</title>
          <description>5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.57"/>
                    <measurement group_id="O2" value="3.0" spread="0.45"/>
                    <measurement group_id="O3" value="3.2" spread="0.43"/>
                    <measurement group_id="O4" value="3.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.60"/>
                    <measurement group_id="O2" value="-0.5" spread="0.64"/>
                    <measurement group_id="O3" value="-0.5" spread="0.51"/>
                    <measurement group_id="O4" value="-0.7" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6</title>
        <description>Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6</title>
          <description>Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.13"/>
                    <measurement group_id="O2" value="-0.3" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.14"/>
                    <measurement group_id="O2" value="-0.6" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.15"/>
                    <measurement group_id="O2" value="-0.8" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9358</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5916</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1790</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BASFI at Week 12</title>
        <description>BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BASFI at Week 12</title>
          <description>BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.98"/>
                    <measurement group_id="O2" value="3.5" spread="2.13"/>
                    <measurement group_id="O3" value="3.5" spread="1.83"/>
                    <measurement group_id="O4" value="3.5" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.78"/>
                    <measurement group_id="O2" value="-1.0" spread="1.64"/>
                    <measurement group_id="O3" value="-0.6" spread="1.97"/>
                    <measurement group_id="O4" value="-1.0" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6</title>
        <description>Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6</title>
          <description>Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.14"/>
                    <measurement group_id="O2" value="-0.9" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.15"/>
                    <measurement group_id="O2" value="-1.1" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.16"/>
                    <measurement group_id="O2" value="-1.4" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6335</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2729</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1559</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BASDAI at Week 12</title>
        <description>BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BASDAI at Week 12</title>
          <description>BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="1.79"/>
                    <measurement group_id="O2" value="4.9" spread="1.80"/>
                    <measurement group_id="O3" value="4.7" spread="1.48"/>
                    <measurement group_id="O4" value="4.9" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.86"/>
                    <measurement group_id="O2" value="-2.1" spread="1.94"/>
                    <measurement group_id="O3" value="-0.6" spread="1.87"/>
                    <measurement group_id="O4" value="-1.4" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20</title>
        <description>Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).</description>
        <time_frame>Weeks 2, 4, 6, 12</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 and Celecoxib 400 mg once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20</title>
          <description>Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=115, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="25.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=116, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=54, 54, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="42.6"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 53, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="32.6"/>
                    <measurement group_id="O4" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6</title>
        <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6</title>
          <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=116, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="1.90"/>
                    <measurement group_id="O2" value="-16.3" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="1.94"/>
                    <measurement group_id="O2" value="-17.1" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="1.95"/>
                    <measurement group_id="O2" value="-19.4" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1111</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3574</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1464</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Pain at Week 12</title>
        <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Pain at Week 12</title>
          <description>100-mm VAS scores specified participant's nocturnal pain in response to the following question &quot;Did you have any pain in the neck, back or hips during the previous night?&quot; 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="20.45"/>
                    <measurement group_id="O2" value="55.1" spread="19.24"/>
                    <measurement group_id="O3" value="54.5" spread="20.14"/>
                    <measurement group_id="O4" value="61.5" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" spread="22.54"/>
                    <measurement group_id="O2" value="-27.5" spread="25.62"/>
                    <measurement group_id="O3" value="-12.5" spread="20.31"/>
                    <measurement group_id="O4" value="-22.6" spread="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6</title>
        <description>Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6</title>
          <description>Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.62"/>
                    <measurement group_id="O2" value="-1.6" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=118, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.69"/>
                    <measurement group_id="O2" value="-2.2" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=118, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="0.67"/>
                    <measurement group_id="O2" value="-3.1" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9641</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7749</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7529</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fingertips to Floor Distance at Week 12</title>
        <description>Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline &lt;0 represented improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fingertips to Floor Distance at Week 12</title>
          <description>Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline &lt;0 represented improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="12.89"/>
                    <measurement group_id="O2" value="17.6" spread="15.23"/>
                    <measurement group_id="O3" value="22.9" spread="19.49"/>
                    <measurement group_id="O4" value="14.6" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="9.38"/>
                    <measurement group_id="O2" value="-3.7" spread="6.82"/>
                    <measurement group_id="O3" value="-3.1" spread="8.18"/>
                    <measurement group_id="O4" value="-1.3" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chest Expansion at Weeks 2, 4, and 6</title>
        <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (&gt;) 0 represented improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 6</time_frame>
        <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chest Expansion at Weeks 2, 4, and 6</title>
          <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (&gt;) 0 represented improvement.</description>
          <population>FAS. N = total evaluable participants. n = evaluable participants at that time point.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=117, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.08"/>
                    <measurement group_id="O2" value="0.3" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=118, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.09"/>
                    <measurement group_id="O2" value="0.4" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=118, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.10"/>
                    <measurement group_id="O2" value="0.6" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 2. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8780</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 4. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2202</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 6. The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5340</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline was analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chest Expansion at Week 12</title>
        <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (&gt;) 0 represented improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chest Expansion at Week 12</title>
          <description>Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (&gt;) 0 represented improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 55, 54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.93"/>
                    <measurement group_id="O2" value="3.8" spread="1.63"/>
                    <measurement group_id="O3" value="3.6" spread="1.82"/>
                    <measurement group_id="O4" value="3.8" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=52, 54, 46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.26"/>
                    <measurement group_id="O2" value="0.8" spread="1.39"/>
                    <measurement group_id="O3" value="0.8" spread="1.29"/>
                    <measurement group_id="O4" value="0.8" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6</title>
        <description>Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6</title>
          <description>Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS</population>
          <units>mm/h</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.30"/>
                    <measurement group_id="O2" value="-1.8" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7003</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR at Week 12</title>
        <description>ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR at Week 12</title>
          <description>ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=54, 54, 52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="14.60"/>
                    <measurement group_id="O2" value="20.8" spread="18.98"/>
                    <measurement group_id="O3" value="22.8" spread="21.99"/>
                    <measurement group_id="O4" value="23.6" spread="19.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=45, 44, 41, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="13.96"/>
                    <measurement group_id="O2" value="-1.3" spread="11.14"/>
                    <measurement group_id="O3" value="-6.3" spread="13.46"/>
                    <measurement group_id="O4" value="-0.7" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP) at Week 6</title>
        <description>C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, 6 Weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP) at Week 6</title>
          <description>C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="1.587"/>
                    <measurement group_id="O2" value="-2.72" spread="1.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-value is for the null hypothesis test H0: u1=u2 vs. H1: u1 is not equal to u2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5183</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline analyzed using ANCOVA with treatment group and investigational centers as factors and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.82</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP at Week 12</title>
        <description>CRP was a marker of inflammation. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS. n = evaluable participants at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
            <description>Celecoxib 200 mg capsule once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP at Week 12</title>
          <description>CRP was a marker of inflammation. Lower values indicated better health. Change from baseline &lt;0 indicated improvement.</description>
          <population>FAS. n = evaluable participants at that time point.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=53, 55, 53, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.53" spread="28.749"/>
                    <measurement group_id="O2" value="15.84" spread="20.464"/>
                    <measurement group_id="O3" value="18.80" spread="25.774"/>
                    <measurement group_id="O4" value="21.01" spread="21.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (n=47, 49, 42, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" spread="9.682"/>
                    <measurement group_id="O2" value="-2.99" spread="13.242"/>
                    <measurement group_id="O3" value="-4.77" spread="24.656"/>
                    <measurement group_id="O4" value="-2.13" spread="20.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Concomitant Use of Paracetamol</title>
        <description>Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6</description>
        <time_frame>Week 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Concomitant Use of Paracetamol</title>
          <description>Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Concomitant Administration of Paracetamol</title>
        <description>Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Concomitant Administration of Paracetamol</title>
          <description>Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.</description>
          <population>FAS</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.08"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paracetamol Tablets Taken Per Day by Participant</title>
        <description>Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.</description>
        <time_frame>Week 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200 mg</title>
            <description>Celecoxib 200 mg capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac SR 75 mg</title>
            <description>Diclofenac SR 75 mg tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Paracetamol Tablets Taken Per Day by Participant</title>
          <description>Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.</description>
          <population>FAS</population>
          <units>tablets per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.16"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib 200 mg</title>
          <description>Celecoxib 200 mg capsule once daily from baseline to Week 6</description>
        </group>
        <group group_id="E2">
          <title>Diclofenac SR 75 mg</title>
          <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6</description>
        </group>
        <group group_id="E3">
          <title>Celecoxib 200 mg, Then Celecoxib 200 mg</title>
          <description>Celecoxib 200 mg capsule once daily from baseline to Week 6, followed by Celecoxib 200 mg capsule once daily from Week 6 to Week 12</description>
        </group>
        <group group_id="E4">
          <title>Diclofenac SR 75 mg, Then Diclofenac SR 75 mg</title>
          <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6 followed by Diclofenac SR 75 mg tablet once daily from Week 6 to Week 12</description>
        </group>
        <group group_id="E5">
          <title>Celecoxib 200 mg, Then Celecoxib 400 mg</title>
          <description>Celecoxib 200 mg capsule once daily from baseline to Week 6, followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
        </group>
        <group group_id="E6">
          <title>Diclofenac SR 75 mg, Then Celecoxib 400 mg</title>
          <description>Diclofenac SR 75 mg tablet once daily from baseline to Week 6, followed by Celecoxib 400 mg capsules once daily from Week 6 to Week 12</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Wolff-Parkinson-White Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Red blood cell urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The protocol does not specify time points for secondary endpoints; these are described in the statistical analysis plan.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

